ARTHROPLASTY
Oral dabigatran as effective as enoxaparin in preventing thromboprophylaxis after THA
This report has been verified
by one or more authors of the
original publication.
Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12
2055 patients undergoing total hip arthroplasty (THA) were randomized to receive oral dabigatran or subcutaneous enoxaparin to compare the impact each pharmaceutical had on the incidence of venous thromboembolism (VTE) and all-cause mortality. Following assessments over a 3 month period, the results displayed that both dabigatran and enoxaparin were equally effective in preventing VTE following THA. Additionally, the risk of bleeding and safety of both drugs were similar.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
